Oligomerix is a biotechnology company based in Bronx, NY, dedicated to developing innovative therapeutics for neurodegenerative diseases characterized by abnormal tau protein, including rare tauopathies and Alzheimer's disease.
The company's lead candidate is a small molecule inhibitor of tau self-association, targeting the early stages of tau aggregation cascade and its progression. Oligomerix's platform also includes a series of second-generation compounds, demonstrating their commitment to advancing disease-modifying treatments for these debilitating conditions.
Generated from the website